search
Back to results

Frontal iTBS for Impulsivity and Suicidal Ideation in Veterans With Mild Traumatic Brain Injury

Primary Purpose

Mild Traumatic Brain Injury, Suicidal Ideation, Impulsivity

Status
Not yet recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
intermittent theta burst stimulation
placebo intermittent theta burst stimulation
Sponsored by
VA Office of Research and Development
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Mild Traumatic Brain Injury focused on measuring brain concussion, brain injuries, traumatic, brain injuries, self-injurious behavior, suicide, attempted, suicide, impulsive behavior, risk-taking, brain diseases, craniocerebral trauma, social problems, mental disorders

Eligibility Criteria

22 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: 22-65 years of age can read and speak English meets criteria for mTBI according to the symptom attribution and classification (SACA) scale Has a C-SSRS (suicidal ideation rating) of >1 within the past month Has a history of impulsivity documented in the medical chart and/or a score of >20 on the UPPS-P negative urgency impulsivity subscale Exclusion Criteria: Has contraindications to iTBS (i.e., epilepsy) Has contraindications to MRI (i.e., claustrophobia, ferromagnetic metal implants) Has an active substance use disorder per the DSM-V criteria Has a history of moderate to severe TBI Has a history of non-traumatic neuroinjury (i.e., stroke, neurosurgery, hemorrhage) Has a history of, or current psychosis not due to an external cause Is pregnant Has an active, unstable medical condition Is within 12 weeks of a major surgery or operation Is within 1 year of TBI

Sites / Locations

  • Edward Hines Jr. VA Hospital, Hines, IL

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

active iTBS

placebo iTBS

Arm Description

Subjects receiving active iTBS treatment

Subjects receiving placebo (sham) iTBS treatment

Outcomes

Primary Outcome Measures

Session Completion Rate
For establish intervention feasibility and tolerability, the study will tract the number of completed iTBS sessions and compute completion percentage rates for each participant.
Change in Social and Occupational Functioning Assessment Scale (SOFAS)
The Social and Occupational Functioning Assessment scale is a rating, given by a trained medical provider, of an individual's ability to perform basic functioning (such as hygiene, maintaining a job, having social relationships). The scale is from 10, meaning unable to function without harming self or others, to 100, meaning superior functioning in all areas. The investigators will be assessing this at subject's baseline, after 1 week of treatment (5 treatment sessions, at the end of week 1) and at study completion (approximately 2 weeks after study starts) to see if there is a change over time in this measure.

Secondary Outcome Measures

Change in Columbia Suicide severity rating scale (C-SSRS)
The C-SSRS is a short questionnaire addressing any recent suicidal thoughts or behaviors that have occurred. A score of 0 means there have been no suicidal thoughts or behaviors, anything above a 0 means some element of suicidality has been experienced by the test-taker. The investigators will be assessing this at subject's baseline, after 1 week of treatment (5 treatment sessions, at the end of week 1), and at study completion (approximately 2 weeks after study starts) to see if there is a change over time in this measure.

Full Information

First Posted
November 15, 2022
Last Updated
September 29, 2023
Sponsor
VA Office of Research and Development
search

1. Study Identification

Unique Protocol Identification Number
NCT05647044
Brief Title
Frontal iTBS for Impulsivity and Suicidal Ideation in Veterans With Mild Traumatic Brain Injury
Official Title
Neuromodulation for Impulsivity and Suicidality in Veterans With Mild Traumatic Brain Injury and Common Co-occurring Mental Health Conditions
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
December 4, 2023 (Anticipated)
Primary Completion Date
March 31, 2028 (Anticipated)
Study Completion Date
March 31, 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
VA Office of Research and Development

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The investigators hope to develop a treatment for suicidal ideation (SI), impulsivity and functional impairments (such as difficulties in social and work settings) that occur after a mild traumatic brain injury (mTBI). These conditions have been shown to be linked. The investigators are using a high-powered magnetic pulse, called intermittent theta burst stimulation (iTBS) applied to the head to see if it can improve these symptoms. The high-powered magnetic pulse causes certain cells in the brain to activate, which seems to strengthen connections between parts of the brain. The purpose of this research is to gather early information on the safety and effectiveness of iTBS provided to the front of the head for impulsivity, SI and functional deficits after mTBI. The investigators plan to use the data collected in this study to develop larger studies in the future. iTBS is FDA approved, but not for these specific symptoms, or in the specific location the investigators are placing it. The investigators are testing to see if its effective for the above conditions when applied to the front of the head.
Detailed Description
Individuals with mild traumatic brain injury (mTBI) are at increased risk of dying by suicide compared to those without - both among Veteran and civilian populations. 22% of Veterans with mTBI report struggling with suicidal ideation (SI). Despite this, there are no effective evidence-based treatments for co-occurring mTBI and SI. Deficits in social and occupational functioning, which often follow mTBI, are strongly related to suicidal ideation (SI) and improvements in these areas are known to lessen SI. Thus, improving function for those with mTBI and SI is of great potential significance. The impulsivity that Veterans with mTBI exhibit is referred to as "negative urgency impulsivity". It often involves aggressive and self-harming behaviors, which impede societal re-integration and rehabilitation. Prior studies indicate negative urgency impulsivity is: (1) a common TBI sequela and (2) a risk factor for SI. Previous studies have also indicated individuals with TBI, SI and negative urgency impulsivity had reduced right-sided ventromedial prefrontal cortex (VMPFC) volume compared to Veterans without these conditions. The VMPFC plays a key role in controlling impulsive limbic responses. These findings are consistent with published reports suggesting individuals with reduced VMPFC volume are more likely to (a) have SI and (b) behave impulsively. Transcranial magnetic stimulation (TMS) holds significant therapeutic promise for post-mTBI SI, impulsivity and functional deficits. TMS induces neuroplasticity, leading to changes that have the potential to improve neurorehabilitation outcomes. TMS is effective for treating post-TBI depression when administered to the dorsolateral prefrontal cortex. Intermittent theta burst stimulation (iTBS) is a "second generation" form of TMS that is delivered more rapidly. It has been proposed that frontal pole TMS could directly strengthen connections throughout the prefrontal cortex, including the VMPFC, thereby dampening limbic system activity. Such a TMS treatment strategy could be used to treat post-mTBI impulsivity and SI, ultimately allowing Veterans to regain functioning. It is not know which Veterans would benefit most from this treatment; examining neural connectivity changes before and after iTBS could determine who would respond to frontal pole iTBS and why. The investigators will conduct a randomized, double-blinded frontal iTBS pilot clinical trial for Veterans with mTBI, impulsivity and SI. As this is a novel treatment approach for this population, this project will focus on testing the safety, feasibility and tolerability of frontal pole iTBS. To inform future research, this project will determine the preliminary effects of iTBS on functioning, negative urgency impulsivity and SI among the pilot sample. This project will also inform future research by examining the relationships between the functional neural connectivity of the VMPFC to the limbic system and how this is affected by iTBS using resting state functional connectivity (rsFC) neuroimaging data, pre- and post-iTBS.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mild Traumatic Brain Injury, Suicidal Ideation, Impulsivity
Keywords
brain concussion, brain injuries, traumatic, brain injuries, self-injurious behavior, suicide, attempted, suicide, impulsive behavior, risk-taking, brain diseases, craniocerebral trauma, social problems, mental disorders

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Model Description
Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P and Magpro C-B60
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
This will be a triple blinded study with participants, investigators and outcomes assessors all masked until study completion.
Allocation
Randomized
Enrollment
55 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
active iTBS
Arm Type
Active Comparator
Arm Description
Subjects receiving active iTBS treatment
Arm Title
placebo iTBS
Arm Type
Placebo Comparator
Arm Description
Subjects receiving placebo (sham) iTBS treatment
Intervention Type
Device
Intervention Name(s)
intermittent theta burst stimulation
Other Intervention Name(s)
iTBS
Intervention Description
intermittent theta burst stimulation (iTBS) will be delivered with the Magventure MagProX100 with MagOption stimulation and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo. The Magventure C-B60 coil will be used to deliver single TMS pulses for motor threshold determination.
Intervention Type
Device
Intervention Name(s)
placebo intermittent theta burst stimulation
Other Intervention Name(s)
placebo iTBS
Intervention Description
intermittent theta burst stimulation (iTBS) will be delivered with the Magventure MagProX100 with MagOption stimulation and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo. The Magventure C-B60 coil will be used to deliver single TMS pulses for motor threshold determination.
Primary Outcome Measure Information:
Title
Session Completion Rate
Description
For establish intervention feasibility and tolerability, the study will tract the number of completed iTBS sessions and compute completion percentage rates for each participant.
Time Frame
Endpoint - after last iTBS session, approximately 2 weeks
Title
Change in Social and Occupational Functioning Assessment Scale (SOFAS)
Description
The Social and Occupational Functioning Assessment scale is a rating, given by a trained medical provider, of an individual's ability to perform basic functioning (such as hygiene, maintaining a job, having social relationships). The scale is from 10, meaning unable to function without harming self or others, to 100, meaning superior functioning in all areas. The investigators will be assessing this at subject's baseline, after 1 week of treatment (5 treatment sessions, at the end of week 1) and at study completion (approximately 2 weeks after study starts) to see if there is a change over time in this measure.
Time Frame
Rated at baseline, study midpoint (at the end of week 1) and study completion, approximately 2 weeks after study begins
Secondary Outcome Measure Information:
Title
Change in Columbia Suicide severity rating scale (C-SSRS)
Description
The C-SSRS is a short questionnaire addressing any recent suicidal thoughts or behaviors that have occurred. A score of 0 means there have been no suicidal thoughts or behaviors, anything above a 0 means some element of suicidality has been experienced by the test-taker. The investigators will be assessing this at subject's baseline, after 1 week of treatment (5 treatment sessions, at the end of week 1), and at study completion (approximately 2 weeks after study starts) to see if there is a change over time in this measure.
Time Frame
Rated at baseline, study midpoint (at the end of week 1) and study completion, approximately 2 weeks after study begins.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
22 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 22-65 years of age can read and speak English meets criteria for mTBI according to the symptom attribution and classification (SACA) scale Has a C-SSRS (suicidal ideation rating) of >1 within the past month Has a history of impulsivity documented in the medical chart and/or a score of >20 on the UPPS-P negative urgency impulsivity subscale Exclusion Criteria: Has contraindications to iTBS (i.e., epilepsy) Has contraindications to MRI (i.e., claustrophobia, ferromagnetic metal implants) Has an active substance use disorder per the DSM-V criteria Has a history of moderate to severe TBI Has a history of non-traumatic neuroinjury (i.e., stroke, neurosurgery, hemorrhage) Has a history of, or current psychosis not due to an external cause Is pregnant Has an active, unstable medical condition Is within 12 weeks of a major surgery or operation Is within 1 year of TBI
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alexandra L Aaronson, MD
Phone
(708) 202-8387
Email
Alexandra.Aaronson@va.gov
First Name & Middle Initial & Last Name or Official Title & Degree
Ibuola Kale
Phone
(708) 202-5898
Email
Ibuola.Kale@va.gov
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alexandra L Aaronson, MD
Organizational Affiliation
Edward Hines Jr. VA Hospital, Hines, IL
Official's Role
Principal Investigator
Facility Information:
Facility Name
Edward Hines Jr. VA Hospital, Hines, IL
City
Hines
State/Province
Illinois
ZIP/Postal Code
60141-3030
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
William Wolf, PhD
Phone
708-202-5689
Email
William.Wolf@va.gov
First Name & Middle Initial & Last Name & Degree
Amanda Smithy
Phone
(708) 202-8387
Ext
25691
Email
Amanda.Smithy@va.gov
First Name & Middle Initial & Last Name & Degree
Alexandra L Aaronson, MD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
A de-identified data set will be created and shared. Final data sets will be made available as per Hines VA Hospital local policy for long term storage and access until enterprise-level resources become available. These data will be available upon request by researchers and scientists in accordance with federal guidelines and Hines local policy. The data provided will be sufficient for anyone to perform analogous or supplemental analyses that would permit validation of the analysis and results. The sharing of data will enable others to evaluate the data and to validate and interpret the data independently. In order to ensure that replication is possible and transparency, statistical code complementary to datasets will be made available through the Federal Interagency Traumatic Brain Injury Research Informatics System
IPD Sharing Time Frame
After primary publication of study data
IPD Sharing Access Criteria
The data will be available upon request by researchers and scientists in accordance with federal guidelines and local policy.
IPD Sharing URL
https://fitbir.nih.gov/

Learn more about this trial

Frontal iTBS for Impulsivity and Suicidal Ideation in Veterans With Mild Traumatic Brain Injury

We'll reach out to this number within 24 hrs